I've always been a little surprised at how willing investors can be to bid up the manufacturers of pharmaceutical components. While these are fine specialty chemical businesses, nothing about the revenue or margins (or the persistence of either) is particularly outstanding. Be that as it may, investors have certainly taken a more positive view on Switzerland's Lonza (OTCPK:LZAGY) over the past 18 months as the company has digested its Arch Chemicals acquisition and a new CEO who appears more focused on margins and returns than growth for the sake of growth.
On one hand, I do like Lonza's capabilities in small molecules, peptides, and monoclonal antibodies. On the other hand, recent contract wins by Samsung Biologics...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: